Subscribe To
Arbutus Provides AB-729 Clinical Data and AB-161 Preclinical Data as Oral Presentations at the Global Hepatitis Summit 2023
Seven patients with cHBV remain off all treatment and continue to maintain low levels of HBV DNA and HBsAg for at least one and half years post- AB-729 treatment AB-161 provides robust anti-HBV activity including suppression of HBV RNA and HBsAg production in preclinical models WARMINSTER, Pa., April 27, 2023 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation […] The post Arbutus Provides AB-729 Clinical Data and AB-161 Preclinical Data as Oral Presentations at the Global Hepatitis...
Read More
Posted: Apr 27 2023, 07:20
Author Name: forextv
Views: 110959